These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35940549)

  • 1. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
    Dupuis-Girod S; Shovlin CL; Kjeldsen AD; Mager HJ; Sabba C; Droege F; Fargeton AE; Fialla AD; Gandolfi S; Hermann R; Lenato GM; Manfredi G; Post MC; Rennie C; Suppressa P; Sure U; ; Buscarini E
    Eur J Med Genet; 2022 Oct; 65(10):104575. PubMed ID: 35940549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT).
    Shovlin CL; Buscarini E; Kjeldsen AD; Mager HJ; Sabba C; Droege F; Geisthoff U; Ugolini S; Dupuis-Girod S
    Orphanet J Rare Dis; 2018 Aug; 13(1):136. PubMed ID: 30111344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
    Buscarini E; Botella LM; Geisthoff U; Kjeldsen AD; Mager HJ; Pagella F; Suppressa P; Zarrabeitia R; Dupuis-Girod S; Shovlin CL;
    Orphanet J Rare Dis; 2019 Feb; 14(1):28. PubMed ID: 30717761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark.
    Hvelplund T; Lange B; Bird SD; Korsholm M; Kjeldsen AD
    Orphanet J Rare Dis; 2022 Jan; 17(1):8. PubMed ID: 34991676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT).
    Eker OF; Boccardi E; Sure U; Patel MC; Alicante S; Alsafi A; Coote N; Droege F; Dupuis O; Fialla AD; Jones B; Kariholu U; Kjeldsen AD; Lefroy D; Lenato GM; Mager HJ; Manfredi G; Nielsen TH; Pagella F; Post MC; Rennie C; Sabbà C; Suppressa P; Toerring PM; Ugolini S; Buscarini E; Dupuis-Girod S; Shovlin CL
    Orphanet J Rare Dis; 2020 Jun; 15(1):165. PubMed ID: 32600364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care.
    Shovlin CL; Buscarini E; Sabbà C; Mager HJ; Kjeldsen AD; Pagella F; Sure U; Ugolini S; Torring PM; Suppressa P; Rennie C; Post MC; Patel MC; Nielsen TH; Manfredi G; Lenato GM; Lefroy D; Kariholu U; Jones B; Fialla AD; Eker OF; Dupuis O; Droege F; Coote N; Boccardi E; Alsafi A; Alicante S; Dupuis-Girod S
    Eur J Med Genet; 2022 Jan; 65(1):104370. PubMed ID: 34737116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
    Shovlin CL; Millar CM; Droege F; Kjeldsen A; Manfredi G; Suppressa P; Ugolini S; Coote N; Fialla AD; Geisthoff U; Lenato GM; Mager HJ; Pagella F; Post MC; Sabbà C; Sure U; Torring PM; Dupuis-Girod S; Buscarini E;
    Orphanet J Rare Dis; 2019 Aug; 14(1):210. PubMed ID: 31462308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series.
    Rosenberg T; Fialla AD; Kjeldsen J; Kjeldsen AD
    Rhinology; 2019 Aug; 57(4):242-251. PubMed ID: 30907391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osler's disease - a disease with a wide variety of clinical manifestations deserving multidisciplinary competence].
    Rönnblom A; Ellingsen J; Frykholm C; Karlsson T; Larsson B; Nelander M; Rorsman F; Thor A; Lidian A
    Lakartidningen; 2022 Aug; 119():. PubMed ID: 36082917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary haemorrhagic telangiectasia: a cause of preventable morbidity and mortality.
    Brady AP; Murphy MM; O'Connor TM
    Ir J Med Sci; 2009 Jun; 178(2):135-46. PubMed ID: 18923886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.
    Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD
    Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
    Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
    Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
    Epperla N; Hocking W
    Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Implementation and development of a center for hereditary hemorrhagic telangiectasia].
    Droege F; Dingemann J; Thangavelu K; Kuerten CHL; Dahlfrancis PM; Kaiser C; Kaster F; Zioga E; Meyer C; Lueb C; Sure U; Lang S; Geisthoff U
    Laryngorhinootologie; 2021 May; 100(5):372-381. PubMed ID: 33723832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.